UOC Neurologia 5
Milan, Milano, 20133, Italy
Location status: Recruiting
NCT Number: NCT04204642
Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients. Although increasingly detected, a number of aspects including the pathophysiology, the clinical and neuroradiological phenotype and the disease course are still under investigation. The incomplete knowledge of the disease limits the implementation of evidence based guidelines on patient's clinical management and the development of treatments able to prevent or reduce disease progression.
The SENECA (SEarchiNg biomarkErs of Cerebral Angiopathy) project is the first Italian multicentre cohort study aimed at better defining the disease natural history and identifying clinical and neuroradiological markers of disease progression. By a multidisciplinary approach and the collection of a large and well phenotyped series and biorepository of CAA patients, the study is ultimately expected to improve the diagnosis and the knowledge of CAA pathophysiological mechanisms.
Interested in participating?
Request Info55 year and older
All sexes
Observational
Milan, Milano, 20133, Italy
Location status: Recruiting
The SENECA is an Italian multicenter network integrating the experience of neurologists, neuroradiologists, neuro-ophthalmologists and biologists and allowing the standardized collection of a well-characterized wide series of sporadic and familial CAA patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
Other names: Prognostic factors evaluation
Time frame: 24 months
description of the phenotypic characteristics of a large population of CAA patients collected in Italy
Time frame: 24 months
Evaluation of the severity of the neuroradiological picture (presence and site of WMHs, CMBs, cSS, CMIs, EPVS ,global cortical atrophy and SAH)
Contact information is provided by the study sponsor or research team.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Other
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA
Acronym: SENECA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06393712
Amyloidosis, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT07250035
Amyloidosis, Brain Diseases
Beijing, China
View Trial DetailsNCT06714097
Amyloidosis, Arterial Occlusive Diseases
Milan, Michigan, Italy
View Trial DetailsNCT05709314
Amyloidosis, Brain Diseases
Phoenix, Arizona, United States
View Trial Details